Am I missing something? Within the next 2-3 weeks, IDIX most likely will get the go ahead/approval of its first drug candidate, telbivudine for treatment of Hepatitis B. Yet the interest level from the investment community "appears" not to see the true value of this achievement, a non-event type attitude.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.